ArticleCancer medicine2026
Temporal Trends in Cause-Specific Cardiovascular Disease Mortality Following Cancer Diagnosis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study analyzed temporal trends in cardiovascular disease (CVD) mortality, stratified by disease type, cancer type, and demographic characteristics.
methodsIndividuals diagnosed with cancer between January 2016 and June 2020 were analyzed using data from the National Cancer Registry in Japan. Standardized mortality ratios (SMRs) were calculated by comparing observed CVD deaths among individuals with cancer to expected deaths in the age- and sex-matched general population. Outcomes included myocardial infarction, other heart diseases, ischemic stroke, hemorrhagic stroke, and all-cause CVD mortality. Multivariable Cox models were developed to estimate hazard ratios for the covariates.
resultsThe analysis included 4,711,540 individuals and 70,630 CVD deaths during the follow-up period. Across all outcomes, SMRs peaked 0-1 month after diagnosis (e.g., 2.35 for all CVDs) and declined sharply by 6 months (e.g., 1.18 for all CVDs). For several CVD outcomes, a secondary increase in SMRs was observed at approximately 37-48 months (e.g., 1.30 for all CVDs). Although the number of deaths for each CVD was higher among older individuals, SMRs were greater in younger age groups. The five most common cancers accounted for approximately half of all deaths and showed similar temporal trends. Cox models achieved moderate predictive accuracy, and adjusted hazard ratios were higher for regional metastasis, distant metastasis, and unknown/other categories than for localized tumors.
conclusionsThis study revealed detailed temporal patterns of CVD mortality following cancer diagnosis, particularly during acute phases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.